Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-08-30
2011-08-30
Sznaidman, Marcos L (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S351000, C514S567000
Reexamination Certificate
active
08008285
ABSTRACT:
The present invention provides methods of treating fibromyalgia or other diseases or conditions causing widespread pain and/or fatigue. In particular, the invention provides pharmaceutical compositions comprising droxidopa alone, or in combination with one or more further active agents, that can be used in the inventive methods. The methods of treatment can comprise treating, preventing, reducing, or eliminating a variety of symptoms recognized as indicative of fibromyalgia, such as chronic pain, allodynia, hyperalgesia, fatigue, sleep disturbance, and depression.
REFERENCES:
patent: 3920728 (1975-11-01), Hegedüs et al.
patent: 4246428 (1981-01-01), Ohashi et al.
patent: 4319046 (1982-03-01), Vacek
patent: 4330558 (1982-05-01), Suzuki et al.
patent: 4421767 (1983-12-01), Palfreyman et al.
patent: 4480109 (1984-10-01), Ohashi et al.
patent: 4497826 (1985-02-01), Narabayashi et al.
patent: 4529603 (1985-07-01), Mori et al.
patent: 4562263 (1985-12-01), Ohashi et al.
patent: 4647587 (1987-03-01), Katsube et al.
patent: 4690949 (1987-09-01), Yoshida et al.
patent: 4699879 (1987-10-01), Umezawa et al.
patent: 4963590 (1990-10-01), Bäckström et al.
patent: 5015564 (1991-05-01), Chari
patent: 5015654 (1991-05-01), Al-Damluji
patent: 5240930 (1993-08-01), Al-Damluji
patent: 5266596 (1993-11-01), Yokokawa et al.
patent: 5616618 (1997-04-01), Takagi
patent: 5656669 (1997-08-01), Nishino
patent: 5739387 (1998-04-01), Oda et al.
patent: 5864041 (1999-01-01), Oda et al.
patent: 6033993 (2000-03-01), Love, Jr. et al.
patent: 6150412 (2000-11-01), Pystynen et al.
patent: 6387936 (2002-05-01), Blanchard-Bregeon et al.
patent: 6512136 (2003-01-01), Benes et al.
patent: 6610324 (2003-08-01), Stoll
patent: 6610690 (2003-08-01), Wong et al.
patent: 6653325 (2003-11-01), Svensson
patent: 6703424 (2004-03-01), Levin et al.
patent: 6746688 (2004-06-01), Kushnir et al.
patent: 6929801 (2005-08-01), Klose et al.
patent: 6992110 (2006-01-01), Kranzler et al.
patent: 2001/0007856 (2001-07-01), Nishino
patent: 2001/0047032 (2001-11-01), Castillo et al.
patent: 2002/0177593 (2002-11-01), Ishihara et al.
patent: 2003/0181509 (2003-09-01), Hinz
patent: 2004/0013620 (2004-01-01), Klose et al.
patent: 2004/0152760 (2004-08-01), Castillo et al.
patent: 2005/0043408 (2005-02-01), Yeboah et al.
patent: 2005/0096387 (2005-05-01), Verheijen et al.
patent: 2005/0233010 (2005-10-01), Satow
patent: 0237 929 (1987-09-01), None
patent: 0 681 838 (1994-04-01), None
patent: 0681838 (1995-11-01), None
patent: 2 200 109 (1988-07-01), None
patent: WO 2004/032844 (2004-04-01), None
patent: WO 2004/100929 (2004-11-01), None
patent: WO 2005/085178 (2005-09-01), None
patent: WO 2007/112014 (2007-10-01), None
patent: WO 2008/003028 (2008-01-01), None
Yunus (Semin. Arthritis Rheum. (2007) 36:339-356).
Mease et. al. (Current pain and headache reports (2008) 12:399-405).
Lawson (Expert Opinion on Investigational drugs (2002) 11:1437-1445).
Goldstein (Cardiovascular Drug Reviews (2006) 24:189-203).
Dadabhoy et. al. (Nature Clinical Practice. Rheumatology (2006) 2:364-372).
Agmo et al., “A Rat Model of Distractibility: Effect of Drugs Modifying Dopaminergic, Noradrenergic and GABA Ergic Neurotransmission,”Journal of Neural Transmission, 1997, pp. 11-29, Vo. 104, No. 1. http://www.spingerlink.com/content
66254211q511485/.
Bennett, et al., “A Peripheral Monoeuropathy in Rat That Produces Disorders of Pain Sensation Like Those Seen in Man,”Pain, 1988, pp. 81-107, vol. 33, No. 1.
Bradley et al., “Orthostatic Hypotension,”American Family Physician, 2003, pp. 2393-2398, vol. 68, No. 12.
Brzostowska et al., “Phenylcarbamates of (−)-Eseroline, (−)-N1-Noreseroline and (−)-Physovenol: Selective Inhibitors of Acetyl and, or Butyrylcholinesterase”,Medical Chemistry Research, 1992, pp. 238-246, vol. 2, No. 4.
Calkins et al., “Relationship Between Chronic Fatigue Syndrome and Neurally Mediated Hypotension,”Cardiology in Review. (1998), pp. 125-134, vol. 6, No. 3.
Cryan et al., “Norepinephrine-Deficient Mice Lack Responses to Antidepressant Drugs, Including Selective Serotonin Reuptake Inhibitors,”PNAS, 2004, pp. 8186-8191, vol. 101, No. 21. www.pnas.org/cgi/doi/10.1073/pnas.0401080101.
Edvinsson et al., “Effect of Exogenous Noradrenaline on Local Cerebral Blood Flow After Osmotic Opening of the Blood-Brain Barrier in the Rat,”J. Physiol., 1978, pp. 149-156, vol. 274.
Flippen-Anderson et al., Thiaphysovenol Phenylcarbamates: X-ray Structures of Biologically Active and Inactive Anticholinesterase Agents,Heterocycles, 1993, pp. 79-86, vol. 36, No. 1.
Greig et al. “Phenserine and Ring C Hetero-Analogues: Drug Candidates for the Treatment of Alzheimer's Disease.”Medicinal Research Reviews. (1995) vol. 15, No. 1, 3-31.
He et al. “Thiaphysovenine and Carbamate Analogues: A New Class of Potent Inhibitors of Cholinesterases.”Medical Chemistry Research. (1992) vol. 2, 229-237.
Iida et al., “Effects of L-Threo-3,4-Dihydroxyphenylserine on Orthostatic Hypotension in Hemodialysis Patients,”American Journal of Nephrology, 2002, pp. 338-346, vol. 22, No. 4, Basel.
Kato et al., “Reversal of the Reserpine-Induced Ptosis by L-Threo-3,4-Dihydroxy-Phenylserine (L-Threo-DOPS), A (−) -Norepinephrine Precursor, and Its Potentiation by Imipramine or Nialamide,”Naunyn-Schmiedeberg's Archies of Pharmacology, 1986, pp. 243-246, vol. 332, No. 3, Berlin.
Kato et al., “Studies on the Activity of L-Threo-3,4-Dihydroxyphenylserine (L-DOPS) As a Catecholamine Precursor in The Brain, Comparison With Taat of L-DOPA,”Biochemical Pharmacology, 1987, pp. 3051-3057, vol. 36, No. 18, Great Britain.
Kawabata et al., “The Noradrenaline Precursor L-Threo-3,4-Dihydroxyphenylserine Exhibits Antinociceptive Activity Via Central Alpha-Adrenoceptors in The Mouse,”Br J. Pharmacol. 1994, pp. 503-508, vol. 111, No. 2, Japan.
Lahiri et al. “Cholinesterase Inhibitors, β-Amyloid Precursor Protein and Amyloid β-Peptides in Alzheimer's Disease.”Acta Neurologica Scandinavia, (Dec. 2000) vol. 102 (s176), 60-67.
Moldes et al. “The Actions of Dihydroxyphenylalanine and Dihydroxyphenylserine On The Sleep-Wakefulness Cycle of The Rat After Peripheral Decarboxylase Inhibition,”Br J Pharmacol, 1975, pp. 101-106, vol. 54, No. 1.
Mori et al., “Effects of L-Erythro-3, 4-Dihydroxyphenylserine On Sleep-Wakefulness Patterns and Concentrations of Brain Catecholamines and Serotonin In Rats,”Jpn J Psychiatry Neurol, 1987, pp. 301-310, vol. 41, No. 2.
Noto et al., “Effects of L-Threo- and Erythro-3,4-Dihydroxyphenylserine on Learning Performance and Concentrations of Brain Noradrenaline and Its Metabolites In Rats,”Pharmacol Biochem Behav., 1992, pp. 215-221, Vo. 43, No. 1.
Pei et al. “Total Synthesis of Racemic and Optically Active Compounds Related to Physostigimine and Ring-C Heteroanalogues from 3 [-2′-(Dimethylamino0ethyl]-2,3-dihydro-5-methoxy-1, 3-dimentyl-1H-indol-2-ol.”Helvetica Chimica ACTA. (1994) vol. 77.
Rowe et al., “Is Neurally Mediated Hypotension an Unrecognised Cause of Chronic Fatigue?”The Lancet, 1995, pp. 623-624, vol. 345.
Russell, “Advances in Fibromyalgia: Possible Role for Central Neurochemicals,”Am J Med Sci., 1998, pp. 377-384, vol. 315, No. 6.
Schondorf, “Acetylcholinesterase Inhibition in the Treatment of Hypotension,”Journal of Neurology Neurosurgery and Psychiatry, 2003, pp. 1187, vol. 74, No. 9, www.jnnp.bmjjournals.com.
Singer et al. “Pyridostigmine Treatment Trial in Neurogenic Orthostatic Hypotension”, 2006,Archives of Neurology. vol. 63, No. 4, pp. 513-518. www.archneur.ama-assn.org.
Takagi et al., “Analgesic Effect of L-Threo-3,4-Dihydroxyphenylserine (L-DOPS) in Patients With Chronic Pain,”Eur Neuropsychopharmacol., 1996, pp. 43-47, vol. 6, No. 1, Japan.
Tanaka et al., “The Effects of the Noradren
Pedder Simon
Roberts Michael J.
Chelsea Therapeutics, Inc.
Sznaidman Marcos L
Womble Carlyle Sandridge & Rice PLLC
LandOfFree
Droxidopa and pharmaceutical composition thereof for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Droxidopa and pharmaceutical composition thereof for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Droxidopa and pharmaceutical composition thereof for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2763011